Stabilized pharmaceutical product
View Patent ↗The invention relates to the use of an adsorbent and a sealed package, for example an overwrap, to protect a pharmaceutical product in a solid state in the presence of a reducing sugar.
1. A method for substantially maintaining fine particle fraction of formoterol fumarate dihydrate in a pharmaceutical product for treating a respiratory disease or disorder, comprising the steps of:
(a) providing a pharmaceutical product that comprises:
(i) a pharmaceutical composition in the solid state comprising formoterol fumarate dihydrate and a reducing sugar;
(ii) an effective amount of an adsorbent material;
(iii) a sealed package substantially impermeable to moisture having an enclosed volume within which the pharmaceutical composition and the adsorbent material are situated; and
(b) contacting formoterol fumarate dihydrate in the pharmaceutical composition with ciclesonide, wherein the ratio of the ciclesonide to formoterol fumarate dihydrate is at least 5:1.
2. The method of claim 1 , wherein the ratio of ciclesonide to formoterol fumarate dihydrate is from about 10:1 to about 100:1.
3. The method of claim 1 , wherein the ciclesonide and the formoterol fumarate dihydrate have a particle size of about 0.1 μm to about 10 μm.
4. The method of claim 1 , wherein greater than about 95% of the ciclesonide and the formoterol fumarate dihydrate have a particle size of less than about 5 μm.
5. The method of claim 1 , wherein the reducing sugar is selected from the group consisting of lactose, glucose, mannose, galactose, maltose, xylose, cellobiose, mellibiose, and maltotriose.
6. The method of claim 1 , wherein the adsorbent material is selected from the group consisting of a molecular sieve, an activated clay, charcoal, an activated alumina, silica, a zeolite, a bauxite, and a mixture thereof.
7. The method of claim 1 , wherein the adsorbent material is 10 Å (Angstrom) molecular sieves.
8. The method of claim 1 , wherein the sealed package is a flexible laminate.
9. The method according to claim 1 , wherein the sealed package is hermetically sealed by heat-sealing, gluing, welding, brazing, mechanical closures, mechanical clamps, or compression.
10. The method of claim 1 , wherein the effective amount of the adsorbent material is that amount to eliminate or reduce formation of Maillard products.
11. The method of claim 1 , wherein the reducing sugar is lactose.
12. The method of claim 1 , wherein the reducing sugar is lactose monohydrate.
13. The method of claim 12 , wherein the lactose monohydrate is non-micronised.
14. The method of claim 1 , wherein the pharmaceutical composition is housed within a dry powder inhaler.
15. The method of claim 14 , wherein said adsorbent material is incorporated into a polymer mixture and manufactured into a plastic component of said dry powder inhaler.
16. The method of claim 1 , wherein said adsorbent material is incorporated into an adhesive.
17. The method of claim 1 , wherein said adsorbent material is in a porous sachet.
18. A method for substantially maintaining fine particle fraction of formoterol fumarate dihydrate in a pharmaceutical product for treating a respiratory disease or disorder, comprising the steps of:
(a) providing a pharmaceutical product that comprises:
(i) a pharmaceutical composition in the solid state comprising formoterol fumarate dihydrate and a reducing sugar;
(ii) an effective amount of an adsorbent material;
(iii) a sealed package substantially impermeable to moisture having an enclosed volume within which the pharmaceutical composition and the adsorbent material are situated; and
(b) contacting formoterol fumarate dihydrate in the pharmaceutical composition with ciclesonide, wherein the ratio of the ciclesonide to formoterol fumarate dihydrate is at least 5:1, wherein the fine particle fraction of formoterol fumarate dihydrate has a diameter of 6 μm or less.
19. The method of claim 18 , wherein the ratio of ciclesonide to formoterol fumarate dihydrate is from about 10:1 to about 100:1.
20. The method of claim 18 , wherein greater than about 95% of the ciclesonide and the formoterol fumarate dihydrate have a diameter of less than about 5 μm.
21. The method of claim 18 , wherein the reducing sugar is selected from the group consisting of lactose, glucose, mannose, galactose, maltose, xylose, cellobiose, mellibiose, and maltotriose.
22. The method of claim 18 , wherein the adsorbent material is selected from the group consisting of a molecular sieve, an activated clay, charcoal, an activated alumina, silica, a zeolite, a bauxite, and a mixture thereof.
23. The method of claim 18 , wherein the adsorbent material is 10 Å (Angstrom) molecular sieves.
24. The method of claim 18 , wherein the sealed package is a flexible laminate.
25. The method according to claim 18 , wherein the sealed package is hermetically sealed by heat-sealing, gluing, welding, brazing, mechanical closures, mechanical clamps, or compression.
26. The method of claim 18 , wherein the effective amount of the adsorbent material is that amount to eliminate or reduce formation of Maillard products.
27. The method of claim 18 , wherein the reducing sugar is lactose.
28. The method of claim 18 , wherein the reducing sugar is lactose monohydrate.
29. The method of claim 28 , wherein the lactose monohydrate is non-micronised.
30. The method of claim 18 , wherein the pharmaceutical composition is housed within a dry powder inhaler.
31. The method of claim 30 , wherein said adsorbent material is incorporated into a polymer mixture and manufactured into a plastic component of said dry powder inhaler.
32. The method of claim 18 , wherein said adsorbent material is incorporated into an adhesive.
33. The method of claim 18 , wherein said adsorbent material is in a porous sachet.